Eficacia de los antivirales en la parálisis de Bell

María Cristina Vázquez; Nury Sánchez; Judith Calvo; Abayubá Perna

María Cristina Vázquez Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Instituto de Neurología, Neurología, Profesora Adjunta
Nury Sánchez Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Instituto de Neurología, Neurología, Asistente
Judith Calvo Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Instituto de Neurología, Neurología, Asistente
Abayubá Perna Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Instituto de Neurología, Neurología, Asistente

Keywords: BELL PALSY, VALACICLOVIR, PREDNISONE, ANTIVIRAL AGENTS, HERPESVIRUS 1 HUMAN

Abstract

Introduction: Bell’s Palsy is a frequent condition, and 15% of patients affected show incomplete recoveries. Over the past years, wide evidence has been gathered as to the possible incidence of Herpes simplex virus type 1 in its etiology.
Objectives: to compare the efficacy of valacyclovir and prednisone versus prednisone plus placebo.
Methods: a prospective, randomized and placebo controlled trial was carried out. Of 41 patients included in the study, 21 were treated with valacy-clovir, 2g a day for seven days, and prednisone; and 19 with prednisone plus placebo, administered orally.
Clinical controls were carried out at weeks 2, 4, 8 and 12. Patients who had incomplete recoveries were followed studied for six months. Recovery was defined as satisfactory when the score was over 90, using a facial paralysis complex scale (FGS – Facial Grading Scale).
Results: no meaningful difference in the evolution of the facial paralysis were found between the two groups.
After six months, recovery was 86.4% in the valacyclo-vir and prednisone group, and 89.5% in the prednisone plus placebo group (p=0,86). Average recovery time was 70.2 and 71.1 days, respectively (p=0,88).
Conclusions: our results fail to prove additional benefits of valacyclovir in the treatment of Bell’s Palsy. According to current evidence available, there is no agreement regarding the antivirals ordinary use in all cases of Bell’s Palsy (NCT00561106).

References

(1) Rowlands S, Hooper R, Hughes R, Burney P. The epidemiology and treatment of Bell’s palsy in the UK. Eur J Neurol 2002; 9(1): 63-7.
(2) Grogan PM, Gronseth GS. Practice parameter: Steroids, acyclovir, and surgery for Bell’s palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 830-6.
(3) Peitersen E. The natural history of Bell’s palsy. Amer J Otol 1982; 4(2): 107-11.
(4) McCormick DP. Herpes simplex virus as a cause of Bell’s palsy. Lancet 1972; 1: 937-9.
(5) Murakami S, Mizobuchi M, Nakashiro Y, Doi T, Hato N, Yanagihara N. Bell’s palsy and herpes simplex virus: Identification of viral DNA in endoneural fluid and muscle. Ann Inter Med 1996; 124: 27-30.
(6) Takasu T, Furuta Y, Sato KC, Fukuda S, Inuyama Y, Nagashima K. Detection of latent herpes simplex virus DNA and RNA in human geniculate ganglia by the polymerase chain reaction. Acta Otolaryngol 1992; 112(6): 1004-11.
(7) Allen D, Dunn L. Aciclovir or valaciclovir for Bell’s palsy (idiopathic facial paralysis). Cochrane Database Syst Rev 2004; (3): CD001869.
(8) Ross BG, Fradet G, Nedzelski JM. Development of a sensitive clinical facial grading system. Otolaryingol Head Neck Surg 1996; 114: 380-6.
(9) Adour KK, Ruboyianes JM, Von Doersten PG, Byl FM, Trent CS, Quesenberry CP, et al. Bell’s palsy treatment with acyclovir and prednisone compared with prednisone alone: a double-blind, randomized, controlled trial. Ann Otol Rhinol Laryngol 1996; 105: 371-8.
(10) De Diego JI, Prim MP, De Sarria MJ, Madero R, Gavila J. Idiopathic facial paralysis: a randomized, prospective, and controlled study using single-dose prednisone versus acyclovir three times daily. Laryngoscope 1998; 108(4): 573-5.
(11) Axelsson S, Lindberg S, Stjernquist-Desatnik A. Outcome of treatment with valacyclovir and prednisone in patients with Bell’s palsy. Ann Otol Rhinol Laryngol 2003; 112(3): 197-01.
(12) Hato N, Matsumoto S, Kisaki H, Takahashi H, Wakisaka H, Honda N, et al. Efficacy of early treatment of Bell’s palsy with oral acyclovir and prednisolone. Otol Neurotol 2003; 24: 948-51.
(13) Sullivan FM, Swan IR, Donnan PT, Morrison JM, Smith BH, McKinstry B, et al. Early treatment with prednisolone or acyclovir in Bell’s palsy. N Engl J Med 2007; 357(16): 1598-07.
(14) Kawaguchi K, Inamura H, Abe Y, Koshu H, Takashita E, Muraki Y, et al. Reactivation of herpes simplex virus type 1 and varicella-zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell’s palsy. Laryngoscope 2007; 117:147-56.
(15) Ramsey MJ, DerSimonian R, Holtel MR, Burgess LPA. Corticosteroid treatment for idiopathic facial nerve paralysis: a meta-analysis. Laryngoscope 2000; 110: 335-41.
(16) Lagalla G, Logullo F, Di Bella P, Provinciali L, Ceravolo MG. Influence of early high-dose steroid treatment on Bell’s palsy evolution Neurol Sci 2002; 23: 107-12.
(17) Steiner I, Mattan Y. Bell’s palsy and herpes viruses: to (acyclo)vir or not to (acyclo)vir? J Neurol Sciences 1999; 170: 19-23.
(18) Baringer JR. Herpes simplex virus and Bell’s palsy. Ann Intern Med 1996; 124: 63-5.

Efficacy of antiviral in treatment of Bell’s Palsy

Abstract

References

Follow on Twitter